85%Confidence
0Views
FDASource
2026-04-05Date
Summary
Cipla's Nilotinib Capsules recall due to stability test failures indicates potential quality control issues at manufacturing facilities, which could impact patient safety and regulatory standing. This may lead to increased scrutiny from the FDA and potential supply disruptions for this cancer medication.
Actionable: Monitor Cipla's manufacturing compliance and consider alternative suppliers for Nilotinib Capsules until quality assurance is confirmed.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now